Jazz Pharmaceuticals (NASDAQ: JAZZ) and Windtree Therapeutics (OTCMKTS:WINT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.
This table compares Jazz Pharmaceuticals and Windtree Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Jazz Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500.
Valuation and Earnings
This table compares Jazz Pharmaceuticals and Windtree Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Jazz Pharmaceuticals||$1.49 billion||6.05||$396.83 million||$6.07||24.74|
|Windtree Therapeutics||$2.04 million||8.09||-$39.49 million||($71.83)||0.00|
Jazz Pharmaceuticals has higher revenue and earnings than Windtree Therapeutics. Windtree Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
90.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Windtree Therapeutics shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Jazz Pharmaceuticals and Windtree Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Jazz Pharmaceuticals presently has a consensus price target of $183.41, suggesting a potential upside of 22.12%. Given Jazz Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Windtree Therapeutics.
Jazz Pharmaceuticals beats Windtree Therapeutics on 12 of the 14 factors compared between the two stocks.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.